ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma"

  • Abstract Number: 1175 • ACR Convergence 2022

    Epigenetic Regulation of MicroRNA-126 in Scleroderma Is Associated with Upregulation of DNA Methyltransferase-1, Repression of Endothelial Nitric Oxide Synthase Expression, and Enhanced Platelet Adhesion to Endothelial Cells

    Yongqing Wang and bashar Kahaleh, University of Toledo, Toledo, OH

    Background/Purpose: SSc vasculopathy is characterized by endothelial injury and deficient endothelial-dependent vasodilation leading to occlusive and proliferative vascular outcomes. Platelet activation and elevated circulating platelet…
  • Abstract Number: 1539 • ACR Convergence 2022

    Gene Expression Meta-Analysis Reveals Aging and Cellular Senescence Signatures in Scleroderma-associated Interstitial Lung Disease

    Monica Yang1, Seoyeon Lee2, Jessica Neely3, Marina Sirota2 and Paul Wolters2, 1UCSF, SF, CA, 2UCSF, SF, 3UCSF Benioff Children's Hospital, San Francisco, CA

    Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by diffuse fibrosis and vasculopathy that has potential to affect nearly every organ system. Interstitial lung…
  • Abstract Number: 2170 • ACR Convergence 2022

    Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis

    Francesco Del Galdo1, Suiyuan Huang2, Lesley-Anne Bissell3, sindhu johnson4, Daniel Furst5 and Dinesh Khanna6, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, 2University of Michigan, Ann Arbor, MI, 3University of Leeds, Leeds, United Kingdom, 4Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, 5University of California Los Angeles, Los Angeles, CA, 6Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: The Ranked Composite Important Difference (RCID) in diffuse cutaneous Systemic Sclerosis ( dcSSc) is a clinically and patient meaningful composite score for outcome of…
  • Abstract Number: 0542 • ACR Convergence 2021

    Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis

    Pamela Palisoc1, Leah Vaikutis1, Ellen Model1, Morgan Omara1, Dinesh Khanna1, Eliza Pei-Suen Tsou1 and Amr Sawalha2, 1University of Michigan, Ann Arbor, MI, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Glycoprotein nonmetastatic melanoma protein B (GPNMB) is widely expressed on stromal cells and immune cells. It is involved in various cell functions such as…
  • Abstract Number: 1643 • ACR Convergence 2021

    Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic

    Xinyu Dou1, David Kaelber2 and Hulya Bukulmez1, 1MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, 2The MetroHealth System Campus of Case Western Reserve University, Cleveland, OH

    Background/Purpose: COVID-19, as a member of the Coronavirus family, has been described to trigger host immune response via type I interferon (IFN) signaling pathways with…
  • Abstract Number: 0557 • ACR Convergence 2021

    The Beta Secretase BACE1 Induces Systemic Sclerosis (SSc) Fibroblast Activation Through the Regulation of the Pro-Fibrotic Notch Signalling Pathway

    Christopher Wasson1, Eva Clavane2, Rebecca Ross1, Paul Meakin2 and Francesco Del Galdo3, 1LIRMM University of Leeds, Leeds, United Kingdom, 2LICAMM University of Leeds, Leeds, United Kingdom, 3University of Leeds, Leeds, United Kingdom

    Background/Purpose: Extensive work in the Alzheimer’s field has shown BACE1 plays an important role in amyloid beta processing. Additionally, there is evidence showing BACE1 regulating…
  • Abstract Number: 1838 • ACR Convergence 2021

    Further Construct Validation of the

    Julia Spierings1, Voon Ong2 and Christopher Denton3, 1University Medical Center Utrecht, Utrecht, Netherlands, 2University College London Medical School Royal Free Campus, London, United Kingdom, 3University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Evaluation of skin is central in clinical management of systemic sclerosis (SSc). Due to the COVID-19 pandemic remote consultations were widely implemented, which inevitably…
  • Abstract Number: 0697 • ACR Convergence 2021

    Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort

    Angeles Shunashy Galindo-Feria1, Begum Horuluoglu1, Jessica Day2, Catia Cerqueira3, Edvard Wigren4, Susanne Gräslund4, Susanna Proudman5, Ingrid E Lundberg4 and Vidya Limaye6, 1Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 2Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia and Discipline of Medicine, University of Adelaide, Adelaide, Australia, 34Dcell, Montreuil, France, 4Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, 5University of Adelaide, Medindie, Australia, 6Royal Adelaide Hospital, Adelaide, Australia

    Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…
  • Abstract Number: 1848 • ACR Convergence 2021

    Untangling the Gut: A Phenome-Wide Association Study of Drugs and Diseases with Gastrointestinal Dysfunction in Systemic Sclerosis

    Rory Maclean1, Fiza Ahmed2, Voon Ong3, Charles Murray4 and Christopher Denton5, 1Royal Free Hospital & University College London, London, United Kingdom, 2Royal Free Hospital, Ilford, United Kingdom, 3University College London Medical School Royal Free Campus, London, United Kingdom, 4Royal Free Hospital, London, United Kingdom, 5University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Gastrointestinal dysfunction (SSc-GI) is a significant burden to patients with systemic sclerosis (SSc), particularly in those with longstanding disease. The management of SSc-GI is…
  • Abstract Number: 0716 • ACR Convergence 2021

    Marked Capillary Basement Membrane Reduplication Is the Hallmark Histopathological Feature of Scleromyositis

    Benjamin Ellezam1, Yves Troyanov2, Valérie Leclair3, Imane Bersali4, Margherita Giannini4, Sabrina Hoa5, Josiane Bourré-Tessier5, Minoru Satoh6, Marvin Fritzler7, Béatrice Lannes8, Jean-Luc Senécal5, Marie Hudson9, Alain Meyer4 and Océane Landon-Cardinal5, 1Division of Pathology, CHU Sainte-Justine; Department of Pathology and Cell Biology, Université de Montréal, Montréal, QC, Canada, 2Division of Rheumatology, Hôpital du Sacré-Coeur; Department of Medicine, Université de Montréal, Montréal, QC, Canada, 3Division of Rheumatology, Jewish General Hospital; Department of Medicine, McGill University, Montréal, QC, Canada, 4Service de physiologie- explorations fonctionnelles musculaire, service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg., Strasbourg, France, 5Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, 6Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, 7University of Calgary, Calgary, AB, Canada, 8Service de Pathologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 9McGill University, Montréal, QC, Canada

    Background/Purpose: Scleromyositis (SM) is an emerging subset of autoimmune myositis (AIM) in patients with features of systemic sclerosis (SSc). SM patients may present without characteristic…
  • Abstract Number: 1849 • ACR Convergence 2021

    False Positive Anti-Topoisomerase I (Scl-70) Antibody Results: A Case Series from a Scleroderma Referral Center

    Brian Lam1, Rana Taherian1, Julio Charles1, Maureen Mayes2, Shervin Assassi3 and Brian Skaug4, 1Division of Rheumatology, University of Texas McGovern Medical School at Houston, Houston, TX, 2Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 3University of Texas McGovern Medical School at Houston, Houston, TX, 4University of Texas McGovern Medical School Houston, Houston, TX

    Background/Purpose: Systemic sclerosis (SSc) is a progressive autoimmune disease with high morbidity and mortality, making early diagnosis and management critical. Anti-Topoisomerase I antibody (anti-Topo I,…
  • Abstract Number: 1090 • ACR Convergence 2021

    Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center

    Diana Prieto-Peña1, Belén Atienza-Mateo2, Miguel Ángel gonzalez-Gay3, Ricardo Blanco4 and Marcos Lopez-Hoyos5, 1Hospital Universitario Marqués de Valdecilla, santander, Spain, 2Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 4Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain

    Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…
  • Abstract Number: 1852 • ACR Convergence 2021

    Healthcare Utilization and Economic Burden in Systemic Sclerosis

    Leonardo Martin Calderon1, Mitali Chaudhary1 and Janet Pope2, 1Western University, London, ON, Canada, 2University of Western Ontario, London, ON, Canada

    Background/Purpose: Systemic Sclerosis (SSc) is a multi-system autoimmune disease, characterized by vasculopathy, fibrosis of the skin and internal organs, and autoimmunity with distinct antibodies. SSc…
  • Abstract Number: 1367 • ACR Convergence 2021

    Associations of Esophageal Dysmotility Patterns with Extra-intestinal Features in Patients with Systemic Sclerosis

    Ana Tucker1, Jamie Perin2, Elizabeth Volkmann3, Ami Shah4, John Pandolfino5 and Zsuzsanna McMahan4, 1Medical University of South Carolina, Charleston, SC, 2Johns Hopkins University, Baltimore, MD, 3Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, 4Johns Hopkins Rheumatology, Baltimore, MD, 5Northwestern University, Chicago, IL

    Background/Purpose: The gastrointestinal (GI) tract is the most commonly affected internal organ in systemic sclerosis (SSc). SSc GI disease is heterogeneous, with some patients experiencing…
  • Abstract Number: 1854 • ACR Convergence 2021

    Disease Characteristics and Social Determinants in African Americans with Systemic Sclerosis: A Single Center Experience

    Sarah Compton, DeAnna Baker Frost, Richard Silver and Diane Kamen, Medical University of South Carolina, Charleston, SC

    Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease categorized on the basis of skin involvement as either limited or diffuse cutaneous SSc, the latter…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology